IperionX addresses ASX query on sharp share price move

IperionX Limited filed a Form 6-K mainly to publish correspondence with the Australian Securities Exchange after a sharp share price move.

Rhea-AI Filing Summary

IperionX Limited filed a Form 6-K mainly to publish correspondence with the Australian Securities Exchange after a sharp share price move. ASX queried a change in IPX’s price from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 on 16 March 2026. IperionX stated it is not aware of any information or reason that would explain the trading pattern, other than previously released disclosures. The company highlighted that its half year report was released last week and noted stakeholder questions about the funding mechanics of its U.S. Department of War grants. IperionX also confirmed it remains in compliance with ASX Listing Rules, including continuous disclosure obligations.

Insights

Equity disclosure analyst

IperionX says it has no undisclosed information explaining the recent share price drop and confirms compliance with disclosure rules.

The correspondence shows IperionX responding to an ASX query after its share price fell from $6.93 to an intraday low of $4.58 over several days. The company explicitly states it is not aware of any specific information that would account for this trading behavior.

IperionX references its recently released half year report and notes investor interest in the funding mechanics of its U.S. Department of War grants, but does not link these directly to the price move. It also confirms compliance with ASX Listing Rule 3.1 on continuous disclosure, indicating no additional material information has been withheld based on the statements provided here.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does IperionX (IPX) disclose in its latest Form 6-K?

IperionX’s Form 6-K publishes its response to an ASX price query. The company addresses a sharp share price move and confirms it is not aware of undisclosed information explaining recent trading, while affirming compliance with ASX continuous disclosure requirements, including Listing Rule 3.1.

Why did ASX question the recent trading in IperionX (IPX) shares?

ASX questioned trading after IperionX’s share price moved from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 on 16 March 2026. Such rapid price changes routinely trigger regulator queries to confirm there is no undisclosed price-sensitive information.

How did IperionX (IPX) respond to the ASX price query?

IperionX responded that it is not aware of any reason or information explaining the recent trading pattern in its securities. The company emphasized that it has already released its half year report and confirmed adherence to ASX Listing Rule 3.1 regarding continuous disclosure obligations.

Does IperionX link its U.S. Department of War grants to the share price move?

IperionX notes stakeholder requests for more detail on funding mechanics of its U.S. Department of War grants but does not state these grants caused the price move. Instead, it simply provides additional context and reiterates there is no known specific reason for the trading behavior.

Is IperionX (IPX) in compliance with ASX Listing Rules after the price query?

Yes. IperionX explicitly confirms it is in compliance with ASX Listing Rules, particularly Listing Rule 3.1 on continuous disclosure. This statement signals that, based on the company’s knowledge, there is no undisclosed material information required to be released at this time.

Who authorized IperionX’s response to the ASX price query?

The response was authorized and approved by IperionX’s Managing Director and CEO, who has delegated authority from the board for disclosure matters. The correspondence was signed on behalf of the company by Company Secretary Louisa Martino, reinforcing formal board-level oversight of disclosure obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 04:19 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

Date: March 16, 2026

Commission File Number: 001-41338

IperionX Limited

(Translation of registrant’s name into English)

1092 Confroy Drive

South Boston, Virginia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:

Exhibit		Description
99.1		ASX Correspondence

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IPERIONX LIMITED
	(registrant)
Date: March 16, 2026	By:	/s/ Marcela Castro

	Name:	Marcela Castro
	Title:	Chief Financial Officer

Exhibit 99.1

March 16, 2026

ASX Compliance

Level 40 Central Park

152-158 St Georges Terrace

PERTH WA 6000

Response to ASX Price Query

IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) provides this response in relation to ASX’s letter dated 16 March 2026 regarding a change in the price of IPX’s securities from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 today.

In response to the questions detailed in ASX’s letter the Company advises as follows:

1. Is IPX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

No.

2. If the answer to question 1 is “yes”

Not applicable.

3. If the answer to question 1 is “no”, is there any other explanation that IPX may have for the recent trading in its securities?

The Company is not aware of any reason or information which could be an explanation for the manner of trading in the Company’s securities over the period.

The Company notes that its half year report was released last week, and it has received requests from stakeholders for further information relating to the funding mechanics of its U.S. Department of War grants, provided below:

1. IperionX makes cash payments for spending upon projects under its U.S. Department of War grants.

2. The U.S. Government subsequently re-imburses IperionX after these payments have been made.

3. For the period to Dec 31, 2025, approximately $6.6 million in payments were incurred that were not yet reimbursed.

4. Under IperionX’s accounting treatment, the Company procures equipment solely in an agency capacity on behalf of the U.S. Government. When an asset is purchased for the U.S. Government, IperionX records a receivable representing the amount due for reimbursement, rather than recognizing the asset or related expense.

5. The U.S. Government can elect to, but is not obliged to, transfer title to all or a portion of equipment or real property to IperionX at the conclusion of the U.S. Department of War projects.

6. As previously disclosed in the December 31, 2025 quarterly activities report, a balance of $46.5 million remains available for reimbursement from the U.S. Government.

4. Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1

The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1. 

5. Approval of responses

The above responses have been authorized and approved by the Managing Director and CEO of IPX with delegated authority from the board to respond to ASX on disclosure matters.

Yours faithfully

IperionX Limited

Louisa Martino

Company Secretary

	Virginia	Tennessee	Utah
1092 Confroy Drive South Boston, VA 24592		279 West Main Street Camden, TN 38320	1782 W 2300 S West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 15.4 KB